Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-28T12:30:21.048Z Has data issue: false hasContentIssue false

128 A single-arm pilot study of an adapted Serious Illness Care Program for older patients with acute myeloid leukemia and myelodysplastic syndromes

Published online by Cambridge University Press:  24 April 2023

Marissa LoCastro
Affiliation:
University of Rochester School of Medicine and Dentistry
Jason Mendler
Affiliation:
Wilmot Cancer Institute
Sally Norton
Affiliation:
University of Rochester School of Nursing
Rachelle Bernacki
Affiliation:
Harvard Medical School
Thomas Carroll
Affiliation:
University of Rochester Medical Center
Heidi Klepin
Affiliation:
Wake Forest School of Medicine
Soroush Mortaz-Hedjri
Affiliation:
University of Rochester Medical Center
Marielle Jensen-Battaglia
Affiliation:
University of Rochester Medical Center
Jane Liesveld
Affiliation:
Wilmot Cancer Institute
Eric Huselton
Affiliation:
Wilmot Cancer Institute
Kristen O’Dwyer
Affiliation:
Wilmot Cancer Institute
Andrea Baran
Affiliation:
University of Rochester Medical Center
Marie Flannery
Affiliation:
University of Rochester School of Nursing
Benzi Kluger
Affiliation:
University of Rochester Medical Center
Kah Poh Loh
Affiliation:
Wilmot Cancer Institute
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/GOALS: We adapted the Serious Illness Care Program (SICP), an evidence-based intervention designed to promote early serious illness conversation, to be delivered via telehealth for older patients with acute myeloid leukemia and myelodysplastic syndromes. The purpose of this study is to assess the feasibility and usability of the adapted intervention. METHODS/STUDY POPULATION: We are conducting a single-arm pilot study of an adapted SICP that is delivered via telehealth for older patients with AML or MDS (>=60 years) and their caregivers (if available). The adapted SICP includes: 1) Patient preparation pamphlet: sent to patient prior the visit with their clinician, 2) Geriatric assessment: completed by study team and provided to clinician prior to their visit with the patient, 3) A 30-60 minute telehealth visit with their primary oncologist or oncology advance practitioner, 4) Serious Illness Conversation Guide (SICG): used by the clinician during the visit to elicit patient values, 5) Family guide: provided to patient following their visit to help patient’s share their values with their family, 6) Electronic medical record note template for clinicians to document their visit the patient. RESULTS/ANTICIPATED RESULTS: We hypothesize that the adapted SICP intervention will be feasible and usable. We will assess feasibility based on retention rate (percent of patients who consent and complete the visit); >80% is considered feasible. Usability will be assessed using the telehealth usability questionnaire; an average score of >5 is considered usable. Other measures include psychological health, advance care planning engagement, quality of life, and disease understanding. We plan to enroll 20 patients in this study. To date, 11 patients have consented to participate, 10 patients have scheduled SICP visits, 9 patients have completed their visits, 7 patients have completed post-intervention qualitative interviews, and 4 patients have completed post-intervention surveys. DISCUSSION/SIGNIFICANCE: The adapted telehealth-based SICP may promote early serious illness conversation, patient-reported outcomes, and end-of-life experience for older patients with AML and MDS. Results from this study will be used to inform development of clinical trials testing the impact of the adapted SICP on patient- and caregiver-reported outcomes.

Type
Evaluation
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2023. The Association for Clinical and Translational Science